1 research outputs found
Progressive Multifocal Leukoencephalopathy associated with the use of Natalizumab in Patient with Multiple Sclerosis. First Case Report in Latin America Hospital de San Jose - Bogota, 2013
La LeucoencefalopatÃa Multifocal Progresiva (LMP) es una condición grave secundaria a la infección por virus
John Cunningham (VJC) derivada de la deficiencia de inmunidad celular innata o adquirida. Se presenta el primer
caso reportado en Latinoamérica de (LMP) asociada a Natalizumab (NZB) en un paciente con diagnóstico de
esclerosis múltiple recaÃda-remisión, quien ingresa a urgencias con cuadro clÃnico de deterioro cognoscitivo,
comportamental, motor y de lenguaje de curso progresivo. Se realizaron neuroimágenes con resonancia magnética
cerebral sugestivas de LMP, estudios de reacción en cadena de polimerasa en lÃquido cefalorraquÃdeo
para virus JC, que resultaron negativos en dos oportunidades; el diagnóstico se confirmó mediante la técnica de
hibridación in situ en biopsia cerebral. Se realiza este reporte con el fin de resaltar la importancia de la vigilancia
clÃnica y paraclÃnica en los pacientes con esclerosis múltiple que reciben NZB.Progressive Multifocal Leukoencephalopathy (PML) is a serious condition secondary to John Cunningham
virus (JCV) infection derived from an innate or acquired cellular immunity deficiency. We present the first
reported case in Latin America of PML associated with Natalizumab (NZB) in a patient with a diagnostic of
relapsing – remitting multiple sclerosis, who entered the emergency room with progressive cognitive, behavioral,
motor and language impairment. Neuroimaging performed with magnetic resonance imaging was suggestive
of PML. Polymerase chain reactions in cerebrospinal fluid for JC virus were conducted twice with negative
results. Finally the diagnosis was confirmed by in situ hybridization technique on brain biopsy. This report
is made in order to highlight the importance of clinical and paraclinical monitoring in patients with multiple
sclerosis receiving NZB